🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

A Global Challenge

Cases of gonorrhoea are increasing worldwide, with figures suggesting in excess of 82 million instances per year. Notably increased rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the face of growing infection rates, the spread of superbugs and the highly restricted treatment choices at this time.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts anticipate that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This medication, which is employed against UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This approval signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

As per data released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the current standard treatment, which involves an injection and a pill. The study enrolled nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of developing nations.

Doctors on the front lines have shared positive views. Access to a easy-to-administer therapy like this is described as a "game-changer" for managing the epidemic. This is considered essential to alleviate the strain of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.